Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment.
Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss.
By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for long-term weight management.
The company recently initiated a phase 1 study in December 2024 for RES-010 in healthy and obese subjects, and they also secured an equity investment from Sanofi in October 2024.
To talk about ways to tackle obesity, and Resalis’ approach, our guest on the podcast this week is Alessandro Toniolo, CEO of Resalis Therapeutics.
00:57-05:06: About Resalis Therapeutics 05:06-08:59: Issues of obesity 08:59-13:20: Companies working on obesity treatments 13:20-15:34: Does suppressing appetite affect nutrition? 15:34-17:49: Introduction of new obesity treatments 17:49-21:33: Approaches other than appetite suppression 21:33-22:38: RES-010 mode of action 22:38-24:04: Administration methods 24:04-25:11: Clinical trials 25:11-26:38: Resalis’ pipeline 26:38-28:08: Next steps for Resalis 28:08-28:36: Effect of obesity on other parts of the body 28:36-29:06: Final comments ` Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Podden och tillhörande omslagsbild på den här sidan tillhör
Labiotech. Innehållet i podden är skapat av Labiotech och inte av,
eller tillsammans med, Poddtoppen.